Disposition of 14677 shares by Ball Titus B. of BeiGene at 15.97 subject to Rule 16b-3
BGNE Stock | USD 190.51 4.05 2.08% |
About 71% of BeiGene's investor base is looking to short. The analysis of the overall investor sentiment regarding BeiGene suggests that many traders are alarmed. The current market sentiment, together with BeiGene's historical and current headlines, can help investors time the market. In addition, many technical investors use BeiGene stock news signals to limit their universe of possible portfolio assets.
BeiGene |
Filed transaction by BeiGene Officer: Principal Accounting Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Cash Flow Correlation
BeiGene's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the BeiGene's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
BeiGene Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards BeiGene can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
BeiGene Fundamental Analysis
We analyze BeiGene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BeiGene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BeiGene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
BeiGene is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
BeiGene Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BeiGene stock to make a market-neutral strategy. Peer analysis of BeiGene could also be used in its relative valuation, which is a method of valuing BeiGene by comparing valuation metrics with similar companies.
Peers
BeiGene Related Equities
APLS | Apellis Pharmaceuticals | 10.88 | ||||
ASND | Ascendis Pharma | 5.85 | ||||
AKRO | Akero Therapeutics | 4.90 | ||||
KRYS | Krystal Biotech | 4.45 | ||||
LEGN | Legend Biotech | 2.99 | ||||
INCY | Incyte | 1.89 | ||||
ARWR | Arrowhead Pharmaceuticals | 1.42 | ||||
BMRN | Biomarin Pharmaceutical | 1.28 | ||||
IMVT | Immunovant | 1.24 | ||||
TVTX | Travere Therapeutics | 1.15 | ||||
IONS | Ionis Pharmaceuticals | 0.21 | ||||
PCVX | Vaxcyte | 0.17 | ||||
IMAB | I Mab | 2.08 | ||||
BPMC | Blueprint Medicines | 2.56 |
Complementary Tools for BeiGene Stock analysis
When running BeiGene's price analysis, check to measure BeiGene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BeiGene is operating at the current time. Most of BeiGene's value examination focuses on studying past and present price action to predict the probability of BeiGene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BeiGene's price. Additionally, you may evaluate how the addition of BeiGene to your portfolios can decrease your overall portfolio volatility.
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |